Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) EBITDA Margin (2016 - 2018)

Armata Pharmaceuticals' EBITDA Margin history spans 6 years, with the latest figure at 326.71% for Q4 2018.

  • For Q4 2018, EBITDA Margin rose 1215171.0% year-over-year to 326.71%; the TTM value through Dec 2018 reached 2495.81%, up 1654450.0%, while the annual FY2024 figure was 762.14%, 291085.0% up from the prior year.
  • EBITDA Margin for Q4 2018 was 326.71% at Armata Pharmaceuticals, down from 2852.44% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 18733.01% in Q3 2014 and bottomed at 73140.91% in Q4 2016.
  • The 5-year median for EBITDA Margin is 2556.23% (2014), against an average of 8285.72%.
  • The largest annual shift saw EBITDA Margin plummeted -144690032bps in 2014 before it skyrocketed 6131591bps in 2017.
  • A 5-year view of EBITDA Margin shows it stood at 2571.29% in 2014, then skyrocketed by 34bps to 1697.9% in 2015, then plummeted by -4208bps to 73140.91% in 2016, then surged by 84bps to 11825.0% in 2017, then soared by 103bps to 326.71% in 2018.
  • Per Business Quant, the three most recent readings for ARMP's EBITDA Margin are 326.71% (Q4 2018), 2852.44% (Q3 2018), and 11825.0% (Q4 2017).